THERAPIX BIOSCI/S (NASDAQ:TRPX) shares rose 6.7% on Tuesday . The stock traded as high as $0.85 and last traded at $0.80, approximately 214,000 shares changed hands during trading. An increase of 10% from the average daily volume of 193,841 shares. The stock had previously closed at $0.75.
Separately, ValuEngine downgraded shares of THERAPIX BIOSCI/S from a “buy” rating to a “hold” rating in a research note on Friday.
The firm’s 50 day moving average is $1.18 and its two-hundred day moving average is $2.09.
About THERAPIX BIOSCI/S (NASDAQ:TRPX)
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Recommended Story: The risks of owning bonds
Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.